Market: NMS |
Currency: USD
Address: Generaal De Wittelaan L11 A3
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Show more
📈 Galapagos NV Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$33.96
-
Upside/Downside from Analyst Target:
-1.27%
-
Broker Call:
-6
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
<0%
-
Upcoming Earnings Date:
2026-02-24
-
EPS Estimate:
1.14
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Galapagos NV
| Date | Reported EPS |
|---|
| 2026-02-23 (estimated upcoming) | - |
| 2025-11-05 | -0.18 |
| 2025-07-23 | -0.93 |
| 2025-04-23 | 0.97 |
| 2025-02-12 | 0.29 |
| 2024-10-30 | -0.74 |
| 2024-08-01 | 0.07 |
| 2024-05-02 | 0.36 |
| 2024-02-21 | -0.88 |
| 2023-11-02 | 0.39 |
| 2023-08-03 | 0.08 |
| 2023-05-04 | 0.35 |
| 2023-02-22 | -3.16 |
| 2022-11-07 | -0.54 |
| 2022-08-08 | -0.29 |
| 2022-05-04 | -0.2 |
| 2022-02-23 | 0.57 |
| 2021-11-04 | -0.98 |
| 2021-08-05 | -0.99 |
| 2021-05-06 | -0.23 |
| 2021-02-18 | -0.84 |
| 2020-11-05 | -1.45 |
| 2020-08-06 | -1.75 |
| 2020-05-08 | -0.46 |
| 2020-03-27 | -1.39 |
📰 Related News & Research
No related articles found for "galapagos nv".
